Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
Cellectar Biosciences, Inc. (CLRB)
Last cellectar biosciences, inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.cellectar.com
Company Research
Source: GlobeNewswire
FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical (“Evestia”), a leading independent global specialist Contract Research Organization (CRO), have entered into an agreement whereby Evestia will provide Cellectar with full CRO services for their upcoming Phase 1b study evaluating CLR 125 for the treatment of triple-negative breast cancer (TNBC). CLR 125 is an iodine-125 Auger-emitting drug candidate targeting solid tumors, such as triple negative breast, lung and colorectal cancers. The new contract will leverage Evestia Clinical’s newly expanded global capabilities and oncology expertise, enhanced by its recent merger with Atlantic Research Group (ARG). Evestia’s experience in oncology spans both adult and pediatric populations, with pa
Show less
Read more
Impact Snapshot
Event Time:
CLRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLRB alerts
High impacting Cellectar Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CLRB
News
- Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 [Yahoo! Finance]Yahoo! Finance
- Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025GlobeNewswire
- Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade GliomaGlobeNewswire
- Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research [Yahoo! Finance]Yahoo! Finance
CLRB
Earnings
- 11/13/25 - Beat
CLRB
Sec Filings
- 11/21/25 - Form 424B3
- 11/14/25 - Form SCHEDULE
- 11/13/25 - Form 8-K
- CLRB's page on the SEC website